Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C Gp120

Background: HVTN 120 is a phase 1/2a randomized double-blind placebo-controlled human immunodeficiency virus (HIV) vaccine trial that evaluated the safety and immunogenicity of ALVAC-HIV (vCP2438) and MF59- or AS01B-adjuvanted bivalent subtype C gp120 Env protein at 2 dose levels in healthy HIV-uninfected adults.

Methods: Participants received ALVAC-HIV (vCP2438) alone or placebo at months 0 and 1. At months 3 and 6, participants received either placebo, ALVAC-HIV (vCP2438) with 200 μg of bivalent subtype C gp120 adjuvanted with MF59 or AS01B, or ALVAC-HIV (vCP2438) with 40 μg of bivalent subtype C gp120 adjuvanted with AS01B. Primary outcomes were safety and immune responses.

Results: We enrolled 160 participants, 55% women, 18-40 years old (median age 24 years) of whom 150 received vaccine and 10 placebo. Vaccines were generally safe and well tolerated. At months 6.5 and 12, CD4+ T-cell response rates and magnitudes were higher in the AS01B-adjuvanted groups than in the MF59-adjuvanted group. At month 12, HIV-specific Env-gp120 binding antibody response magnitudes in the 40 μg gp120/AS01B group were higher than in either of the 200 μg gp120 groups.

Conclusions: The 40 μg dose gp120/AS01B regimen elicited the highest CD4+ T-cell and binding antibody responses. Clinical Trials Registration . NCT03122223.

References

Kensil C, Patel U, Lennick M, Marciani D . Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol. 1991; 146(2):431-7. View

Tomaras G, Yates N, Liu P, Qin L, Fouda G, Chavez L . Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol. 2008; 82(24):12449-63. PMC: 2593361. DOI: 10.1128/JVI.01708-08. View

Gray G, Bekker L, Laher F, Malahleha M, Allen M, Moodie Z . Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults. N Engl J Med. 2021; 384(12):1089-1100. PMC: 7888373. DOI: 10.1056/NEJMoa2031499. View

Evans T, McElrath M, Matthews T, Montefiori D, Weinhold K, Wolff M . QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine. 2001; 19(15-16):2080-91. DOI: 10.1016/s0264-410x(00)00415-1. View

Trkola A, Matthews J, Gordon C, Ketas T, Moore J . A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J Virol. 1999; 73(11):8966-74. PMC: 112928. DOI: 10.1128/JVI.73.11.8966-8974.1999. View

Moodie Z, Dintwe O, Sawant S, Grove D, Huang Y, Janes H . Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk. J Infect Dis. 2022; 226(2):246-257. PMC: 9890908. DOI: 10.1093/infdis/jiac260. View

Nitayaphan S, Pitisuttithum P, Karnasuta C, Eamsila C, de Souza M, Morgan P . Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis. 2004; 190(4):702-6. DOI: 10.1086/422258. View

Pollara J, Hart L, Brewer F, Pickeral J, Packard B, Hoxie J . High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A. 2011; 79(8):603-12. PMC: 3692008. DOI: 10.1002/cyto.a.21084. View

Horton H, Thomas E, Stucky J, Frank I, Moodie Z, Huang Y . Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods. 2007; 323(1):39-54. PMC: 2683732. DOI: 10.1016/j.jim.2007.03.002. View

10.

Mosca F, Tritto E, Muzzi A, Monaci E, Bagnoli F, Iavarone C . Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci U S A. 2008; 105(30):10501-6. PMC: 2483233. DOI: 10.1073/pnas.0804699105. View

11.

Yates N, deCamp A, Korber B, Liao H, Irene C, Pinter A . HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. J Virol. 2018; 92(8). PMC: 5874409. DOI: 10.1128/JVI.01843-17. View

12.

Lin L, Finak G, Ushey K, Seshadri C, Hawn T, Frahm N . COMPASS identifies T-cell subsets correlated with clinical outcomes. Nat Biotechnol. 2015; 33(6):610-6. PMC: 4569006. DOI: 10.1038/nbt.3187. View

13.

Van Braeckel E, Bourguignon P, Koutsoukos M, Clement F, Janssens M, Carletti I . An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers. Clin Infect Dis. 2011; 52(4):522-31. PMC: 3060898. DOI: 10.1093/cid/ciq160. View

14.

De Becker G, Moulin V, Pajak B, BRUCK C, Francotte M, Thiriart C . The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Int Immunol. 2000; 12(6):807-15. DOI: 10.1093/intimm/12.6.807. View

15.

Haynes B, B Gilbert P, McElrath M, Zolla-Pazner S, Tomaras G, Alam S . Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012; 366(14):1275-86. PMC: 3371689. DOI: 10.1056/NEJMoa1113425. View

16.

Seubert A, Monaci E, Pizza M, OHagan D, Wack A . The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol. 2008; 180(8):5402-12. DOI: 10.4049/jimmunol.180.8.5402. View

17.

Agnandji S, Lell B, Soulanoudjingar S, Fernandes J, Abossolo B, Conzelmann C . First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med. 2011; 365(20):1863-75. DOI: 10.1056/NEJMoa1102287. View

18.

Yates N, Liao H, Fong Y, deCamp A, Vandergrift N, Williams W . Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med. 2014; 6(228):228ra39. PMC: 4116665. DOI: 10.1126/scitranslmed.3007730. View

19.

De Gregorio E, Caproni E, Ulmer J . Vaccine adjuvants: mode of action. Front Immunol. 2013; 4:214. PMC: 3728558. DOI: 10.3389/fimmu.2013.00214. View

20.

Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R . Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009; 361(23):2209-20. DOI: 10.1056/NEJMoa0908492. View